Catabasis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CATB)

$1.74 +0.06 (+3.57 %)
(As of 02/25/2018 03:06 PM ET)
Previous Close$1.74
Today's Range$1.62 - $1.81
52-Week Range$1.09 - $3.78
Volume1.47 million shs
Average Volume2.17 million shs
Market Capitalization$40.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2

About Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971

Debt

Debt-to-Equity RatioN/A
Current Ratio3.02%
Quick Ratio3.02%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.56 per share
Price / Book1.12

Profitability

Trailing EPS($1.51)
Net Income$-36,060,000.00
Net MarginsN/A
Return on Equity-135.85%
Return on Assets-95.96%

Miscellaneous

Employees38
Outstanding Shares23,080,000

Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) posted its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The biotechnology company earned $0.25 million during the quarter. View Catabasis Pharmaceuticals' Earnings History.

When will Catabasis Pharmaceuticals make its next earnings announcement?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Catabasis Pharmaceuticals.

Where is Catabasis Pharmaceuticals' stock going? Where will Catabasis Pharmaceuticals' stock price be in 2018?

6 analysts have issued 12-month target prices for Catabasis Pharmaceuticals' stock. Their forecasts range from $2.00 to $9.00. On average, they anticipate Catabasis Pharmaceuticals' share price to reach $5.33 in the next twelve months. View Analyst Ratings for Catabasis Pharmaceuticals.

Who are some of Catabasis Pharmaceuticals' key competitors?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:

  • Kenneth M. Bate, Co-Chairman of the Board (Age 66)
  • Michael Jay Ross Ph. D., Director, Co-Chairman of the Board of Directors (Age 67)
  • Jill C. Milne Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 49)
  • Deirdre A. Cunnane J.D., Senior Vice President, General Counsel, Treasurer (Age 52)
  • Andrew Nichols Ph.D., Chief Scientific Officer (Age 56)
  • Joanne M. Donovan M.D. Ph.D., Chief Medical Officer (Age 60)
  • Edward Hibben, Chief Business Officer (Age 58)
  • Burt A. Adelman M.D., Independent Director (Age 65)
  • Jean M. George, Independent Director (Age 59)
  • Michael D. Kishbauch, Independent Director (Age 68)

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Who owns Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include CORRIENTE ADVISORS, LLC (7.30%), Renaissance Technologies LLC (2.03%), Deutsche Bank AG (0.98%) and Geode Capital Management LLC (0.33%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Who bought Catabasis Pharmaceuticals stock? Who is buying Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG and Geode Capital Management LLC. View Insider Buying and Selling for Catabasis Pharmaceuticals.

How do I buy Catabasis Pharmaceuticals stock?

Shares of Catabasis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of Catabasis Pharmaceuticals stock can currently be purchased for approximately $1.74.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $40.16 million. The biotechnology company earns $-36,060,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Catabasis Pharmaceuticals employs 38 workers across the globe.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is One Kendall Square Bldg. 1400E Suite B14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


MarketBeat Community Rating for Catabasis Pharmaceuticals (CATB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Catabasis Pharmaceuticals (NASDAQ:CATB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.832.60
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.33$5.33$5.33$5.25
Price Target Upside: 241.88% upside223.23% upside229.22% upside341.18% upside

Catabasis Pharmaceuticals (NASDAQ:CATB) Consensus Price Target History

Price Target History for Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals (NASDAQ:CATB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018WedbushReiterated RatingOutperform$5.00 -> $4.00HighView Rating Details
11/20/2017CitigroupUpgradeNeutral -> Buy$3.00N/AView Rating Details
10/6/2017CowenReiterated RatingMarket Perform$2.00N/AView Rating Details
10/5/2017CIBCReiterated RatingOutperform -> Outperform$4.00 -> $7.00N/AView Rating Details
10/5/2017OppenheimerBoost Price TargetOutperform$4.00 -> $7.00N/AView Rating Details
8/14/2017HC WainwrightBoost Price TargetBuy$8.00 -> $9.00MediumView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Catabasis Pharmaceuticals (NASDAQ:CATB) Earnings History and Estimates Chart

Earnings by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals (NASDAQ CATB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.33)N/AView Earnings Details
11/9/2017Q3 2017($0.33)($0.31)$0.25 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.40)($0.32)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.45)($0.41)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.49)($0.47)ViewN/AView Earnings Details
11/10/2016Q316($0.65)($0.54)ViewListenView Earnings Details
8/11/2016Q216($0.65)($0.61)ViewListenView Earnings Details
5/12/2016Q1($0.64)($0.61)ViewListenView Earnings Details
3/2/2016Q415($0.69)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.64)($0.55)ViewListenView Earnings Details
8/13/2015Q2 2015($0.70)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Catabasis Pharmaceuticals (NASDAQ:CATB) Earnings Estimates

2018 EPS Consensus Estimate: ($1.21)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.31)($0.31)($0.31)
Q3 20181($0.32)($0.32)($0.32)
Q4 20181($0.32)($0.32)($0.32)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Catabasis Pharmaceuticals (NASDAQ:CATB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Catabasis Pharmaceuticals (NASDAQ CATB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 40.70%
Institutional Ownership Percentage: 32.40%
Insider Trades by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Institutional Ownership by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals (NASDAQ CATB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2015Medimmune Ventures, Inc.Major ShareholderBuy223,439$12.00$2,681,268.00View SEC Filing  
6/30/2015Nicholas GalakatosDirectorBuy376,695$12.00$4,520,340.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Catabasis Pharmaceuticals (NASDAQ CATB) News Headlines

Source:
DateHeadline
Catabasis Has The Potential To Provide Edasalonexent As Treatment For The Entire DMD Population Not Just A ... - Seeking AlphaCatabasis Has The Potential To Provide Edasalonexent As Treatment For The Entire DMD Population Not Just A ... - Seeking Alpha
seekingalpha.com - February 22 at 8:21 AM
Catabasis Pharmaceuticals Inc (CATB) Receives Consensus Rating of "Buy" from BrokeragesCatabasis Pharmaceuticals Inc (CATB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 20 at 2:54 PM
Its Time To Invest In Catabasis Pharmaceuticals Following Impressive Phase 2 DMD Data - Seeking AlphaIt's Time To Invest In Catabasis Pharmaceuticals Following Impressive Phase 2 DMD Data - Seeking Alpha
seekingalpha.com - February 17 at 8:14 AM
Research Analysts Issue Forecasts for Catabasis Pharmaceuticals Incs FY2022 Earnings (CATB)Research Analysts Issue Forecasts for Catabasis Pharmaceuticals Inc's FY2022 Earnings (CATB)
www.americanbankingnews.com - February 15 at 4:28 PM
Catabasis Pharmaceuticals (CATB) "Outperform" Rating Reiterated at WedbushCatabasis Pharmaceuticals' (CATB) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - February 14 at 8:52 PM
Today’s Research Reports on Trending Tickers: Catabasis Pharmaceuticals and ImmunoCellular TherapeuticsToday’s Research Reports on Trending Tickers: Catabasis Pharmaceuticals and ImmunoCellular Therapeutics
finance.yahoo.com - February 14 at 9:43 AM
Why Catabasis Is Tuesday’s Biggest WinnerWhy Catabasis Is Tuesday’s Biggest Winner
www.msn.com - February 13 at 3:43 PM
ETF Preview: ETFs, Futures Firmer Ahead as Street Mull Mester Comments, Small Business Optimism IndexETF Preview: ETFs, Futures Firmer Ahead as Street Mull Mester Comments, Small Business Optimism Index
www.nasdaq.com - February 13 at 9:50 AM
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of TreatmentCatabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment
finance.yahoo.com - February 13 at 9:50 AM
Catabasis Pharmaceuticals (CATB) Stock Rating Lowered by Zacks Investment ResearchCatabasis Pharmaceuticals (CATB) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 29 at 9:36 PM
Catabasis Pharmaceuticals (CATB) Stock Rating Upgraded by Zacks Investment ResearchCatabasis Pharmaceuticals (CATB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 26 at 7:04 PM
Catabasis Pharmaceuticals Inc (CATB) Receives Average Rating of "Buy" from AnalystsCatabasis Pharmaceuticals Inc (CATB) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 26 at 8:54 AM
Catabasis Pharmaceuticals (CATB) Downgraded by Zacks Investment ResearchCatabasis Pharmaceuticals (CATB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 18 at 7:42 PM
Catabasis Pharmaceuticals (CATB) Upgraded to Buy at Zacks Investment ResearchCatabasis Pharmaceuticals (CATB) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - January 17 at 9:14 PM
Catabasis Pharmaceuticals (CATB) Rating Lowered to Hold at Zacks Investment ResearchCatabasis Pharmaceuticals (CATB) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 10 at 7:46 PM
Catabasis Pharmaceuticals Inc (CATB) Given Consensus Rating of "Buy" by BrokeragesCatabasis Pharmaceuticals Inc (CATB) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 1 at 8:02 AM
Catabasis Pharmaceuticals (CATB) Rating Reiterated by WedbushCatabasis Pharmaceuticals (CATB) Rating Reiterated by Wedbush
www.americanbankingnews.com - December 15 at 8:38 PM
Catabasis Pharmaceuticals, Inc. (CATB) Receives Average Recommendation of "Buy" from AnalystsCatabasis Pharmaceuticals, Inc. (CATB) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 7 at 8:00 AM
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne ... - GlobeNewswire (press release)Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne ... - GlobeNewswire (press release)
globenewswire.com - December 6 at 5:01 PM
Summit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness DaySummit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness Day
finance.yahoo.com - December 6 at 10:02 AM
Catabasis Pharmaceuticals (CATB) and The Competition Critical ContrastCatabasis Pharmaceuticals (CATB) and The Competition Critical Contrast
www.americanbankingnews.com - November 23 at 5:24 AM
Annual Piper Jaffray Healthcare Conference - Business Wire (press release)Annual Piper Jaffray Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 21 at 5:09 PM
Catabasis Pharmaceuticals to Present at 29th Annual Piper Jaffray Healthcare ConferenceCatabasis Pharmaceuticals to Present at 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 21 at 5:09 PM
Catabasis Pharmaceuticals, Inc. (CATB) Stock Rating Upgraded by Citigroup Inc.Catabasis Pharmaceuticals, Inc. (CATB) Stock Rating Upgraded by Citigroup Inc.
www.americanbankingnews.com - November 20 at 8:52 PM
Catabasis Pharmaceuticals, Inc. (CATB) Upgraded to "Buy" by Zacks Investment ResearchCatabasis Pharmaceuticals, Inc. (CATB) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 16 at 5:32 PM
Catabasis Pharmaceuticals, Inc. (CATB) Short Interest Down 62.5% in OctoberCatabasis Pharmaceuticals, Inc. (CATB) Short Interest Down 62.5% in October
www.americanbankingnews.com - November 13 at 2:32 AM
Catabasis Pharmaceuticals, Inc. (CATB) Receives Average Recommendation of "Buy" from BrokeragesCatabasis Pharmaceuticals, Inc. (CATB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 9:16 AM
Edited Transcript of CATB earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of CATB earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 11 at 11:54 AM
Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings CallInvestor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call
www.finanznachrichten.de - November 10 at 4:32 PM
Catabasis Pharmaceuticals, Inc. (CATB) Issues  Earnings ResultsCatabasis Pharmaceuticals, Inc. (CATB) Issues Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM
Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress - Business Wire (press release)Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress - Business Wire (press release)
www.businesswire.com - November 9 at 7:36 PM
Catabasis Pharmaceuticals Inc to Host Earnings CallCatabasis Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - November 9 at 7:35 PM
Is Catabasis Pharmaceuticals Inc (CATB) A Financially Sound Company?Is Catabasis Pharmaceuticals Inc (CATB) A Financially Sound Company?
finance.yahoo.com - November 9 at 7:35 PM
Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business ProgressCatabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress
finance.yahoo.com - November 9 at 7:35 PM
Catabasis Pharmaceuticals posts 3Q lossCatabasis Pharmaceuticals posts 3Q loss
finance.yahoo.com - November 9 at 7:35 PM
Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on ... - Business Wire (press release)Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on ... - Business Wire (press release)
www.businesswire.com - November 2 at 5:45 PM
Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, November 9Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, November 9
finance.yahoo.com - November 2 at 5:45 PM
Catabasis Pharmaceuticals, Inc. (CATB) to Release Earnings on WednesdayCatabasis Pharmaceuticals, Inc. (CATB) to Release Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:28 AM
Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis ConferenceCatabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference
www.businesswire.com - October 26 at 5:07 PM
Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic ... - Business Wire (press release)Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic ... - Business Wire (press release)
www.businesswire.com - October 26 at 8:39 AM
Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis ConferenceCatabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference
finance.yahoo.com - October 26 at 8:39 AM
Catabasis Pharmaceuticals, Inc. (CATB) Given Average Recommendation of "Buy" by BrokeragesCatabasis Pharmaceuticals, Inc. (CATB) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 18 at 11:20 AM
Zacks Investment Research Downgrades Catabasis Pharmaceuticals, Inc. (CATB) to HoldZacks Investment Research Downgrades Catabasis Pharmaceuticals, Inc. (CATB) to Hold
www.americanbankingnews.com - October 16 at 8:44 PM
FY2019 EPS Estimates for Catabasis Pharmaceuticals, Inc. (CATB) Cut by AnalystFY2019 EPS Estimates for Catabasis Pharmaceuticals, Inc. (CATB) Cut by Analyst
www.americanbankingnews.com - October 9 at 8:20 AM
Cowen and Company Reiterates "Market Perform" Rating for Catabasis Pharmaceuticals, Inc. (CATB)Cowen and Company Reiterates "Market Perform" Rating for Catabasis Pharmaceuticals, Inc. (CATB)
www.americanbankingnews.com - October 6 at 1:44 PM
Catabasis Pharmaceuticals, Inc. (CATB) Given New $3.50 Price Target at Citigroup Inc.Catabasis Pharmaceuticals, Inc. (CATB) Given New $3.50 Price Target at Citigroup Inc.
www.americanbankingnews.com - October 5 at 4:20 PM
Catabasis DMD Candidate Slows Disease Progression, Stock UpCatabasis' DMD Candidate Slows Disease Progression, Stock Up
finance.yahoo.com - October 5 at 3:53 PM
Catabasis Pharmaceuticals, Inc. (CATB) Earns Outperform Rating from CIBCCatabasis Pharmaceuticals, Inc. (CATB) Earns Outperform Rating from CIBC
www.americanbankingnews.com - October 5 at 1:33 PM
Catabasis Pharma (CATB) Announces Positive Results from Extension of Phase 2 MoveDMD Trial Evaluating EdasalonexentCatabasis Pharma (CATB) Announces Positive Results from Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent
www.streetinsider.com - October 5 at 11:47 AM
Todays Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta PharmaceuticalsToday's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals
finance.yahoo.com - October 5 at 11:47 AM

SEC Filings

Catabasis Pharmaceuticals (NASDAQ:CATB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Catabasis Pharmaceuticals (NASDAQ:CATB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Catabasis Pharmaceuticals (NASDAQ CATB) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.